These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12384378)

  • 1. Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate.
    Trampuz A; Laifer G; Wenk M; Rajacic Z; Zimmerli W
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3630-3. PubMed ID: 12384378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid.
    Trampuz A; Wenk M; Rajacic Z; Zimmerli W
    Antimicrob Agents Chemother; 2000 May; 44(5):1352-5. PubMed ID: 10770776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1665-70. PubMed ID: 12019073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio.
    Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH; Firsov AA
    Antimicrob Agents Chemother; 2000 Apr; 44(4):879-84. PubMed ID: 10722485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.
    Lister PD
    Antimicrob Agents Chemother; 2002 Jan; 46(1):69-74. PubMed ID: 11751113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.
    Zinner SH; Firsov AA; Gilbert D; Simmons K; Lubenko IY
    J Antimicrob Chemother; 2001 Dec; 48(6):821-6. PubMed ID: 11733466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.
    Boos M; Mayer S; Fischer A; Köhrer K; Scheuring S; Heisig P; Verhoef J; Fluit AC; Schmitz FJ
    Antimicrob Agents Chemother; 2001 Mar; 45(3):938-42. PubMed ID: 11181385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal mechanism of gatifloxacin compared with other quinolones.
    Gradelski E; Kolek B; Bonner D; Fung-Tomc J
    J Antimicrob Chemother; 2002 Jan; 49(1):185-8. PubMed ID: 11751786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998.
    Huczko E; Conetta B; Bonner D; Valera L; Stickle T; Macko A; Fung-Tomc J
    Int J Antimicrob Agents; 2000 Dec; 16(4):401-5. PubMed ID: 11118848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic assessment of gatifloxacin against Streptococcus pneumoniae.
    Mattoes HM; Banevicius M; Li D; Turley C; Xuan D; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2092-7. PubMed ID: 11408228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1308-12. PubMed ID: 12654663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
    Kays MB; Conklin M
    Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
    Aliabadi FS; Lees P
    J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.